The Readout Loud

Latest Episodes:

237: The 'electric vehicles' of pharma, Illumina's boondoggle, & a Theranos sentencing Dec 08, 2022

Show notes

STAT's Elaine Chen joins us to explain how the escalating demand for a potent diabetes drug is putting patients with obesity in a difficult situation. We also discuss a curious trend in biotech investing, the future of Illumina, and another sentencing in the Theranos saga.

236: Wither PhRMA, Alzheimer's treatment data revealed, and the first fecal microbiome drug approval Dec 01, 2022

Show notes

STAT Washington correspondent Rachel Cohrs joins us to explain how PhRMA, the all-powerful lobbying group, lost its edge in a fight over drug-pricing negotiation. Damian gives us the inside scoop on CTAD, the big Alzheimer's disease research conference, where Eisai and Biogen presented groundbreaking data on their treatment called lecanemab. We also discuss the FDA approval of a microbiome drug for the treatment of a bowel disorder and the potential for a big acquisition of Horizon Therapeutics.

235: LIVE from the STAT Summit Nov 17, 2022

Show notes

How do Alzheimer’s drugs even work? Can biotech people bake? And do we even like one another? Recorded live from the 2022 STAT Summit, we discuss the failure of an Alzheimer’s disease treatment from Roche, the unexpected success of a competing one for Eisai, and some unpredictable questions from our audience.

234: Biogen's new CEO, how the midterms affect science, & a biotech bankruptcy Nov 10, 2022

Show notes

STAT Washington correspondent Sarah Owermohle joins us to explain how this week's midterm elections will affect health and medicine, and what the politicization of the pandemic means for the future of science in the U.S. We also discuss the incoming CEOs of Biogen and Seagen, plus a pair of biotech collapses.

233: How the biotech revolution could come apart at the seams Nov 03, 2022

Show notes

Our colleague Matthew Herper joins us to discuss his thoughtful, personal story on how the biotech revolution that brought us genome editing, Covid-19 vaccines, and lifesaving medicines could run aground if humanity can't get out of its own way.

232: Anti-science at the polls, a biotech odd couple, & the stakes of the midterms Oct 27, 2022

Show notes

Our colleague Sarah Owermohle joins us to discuss how pandemic shutdowns, Covid-19 vaccines, and the prospect of arresting Anthony Fauci have become campaign rallying cries in midterm elections. We also discuss the latest news in the life sciences, including the potential effects of federal drug-price negotiation and the virtues of befriending Pharrell Williams.

231: BU's Covid tinkering, FDA on trial, & why it's hard to take drugs off the market Oct 20, 2022

Show notes

Lawyer and bioethicist Holly Fernandez Lynch joins us to explain a watershed test of the FDA's authority to revoke drug approvals. And STAT's Helen Branswell calls in to discuss the headline-grabbing research at Boston University involving a lab-developed version of the virus that causes Covid-19.

230: BIO's messy transition, mRNA's future, & Biogen's next CEO Oct 13, 2022

Show notes

STAT Washington correspondent Rachel Cohrs joins us to explain the abrupt departure of the CEO of BIO, the lobbying group representing biotech on Capitol Hill, and its wider implications. We also discuss the latest news in the life sciences, including the future of mRNA, a promising startup closing its doors, and Biogen’s search for a new CEO.

229: Nobels for science, biotech dealmaking, & a friendly FTC Oct 06, 2022

Show notes

The newest Nobel laureates got their phone calls from Stockholm this week, and STAT science writer Megan Molteni joins us to explain their prize-winning work in medicine and chemistry. We also discuss the latest news in the life sciences, including the state of biotech dealmaking and the evolution of Amylyx Pharmaceuticals.

228: A surprise success in Alzheimer's and how FDA history seeded modern controversy Sep 29, 2022

Show notes

Lecanemab, a new Alzheimer's treatment from partners Biogen and Eisai, succeeded in a pivotal clinical trial, and we explain the surprising development and its sweeping implications. Then, oncologist Mikkael Sekeres joins us to talk about his new book, which is a history of the FDA and an insider’s look at one of the agency’s most contentious drug approval hearings.

Our TOPPODCAST Picks

Follow Us

Stay Connected

Related Podcasts

Links

Stay Connected